@article {Montemurro:1 April 2007:0923-7534:665,
	author = "Montemurro, M",
	author = "Kiefer, T",
	author = "Schuler, F",
	author = "Al-Ali, HK",
	author = "Wolf, H-H",
	author = "Herbst, R",
	author = "Haas, A",
	author = "Helke, K",
	author = "Theilig, A",
	author = "Lotze, C",
	author = "Hirt, C",
	author = "Niederwieser, D",
	author = "Schwenke, M",
	author = "For the Ostdeutsche Studiengruppe Hamatologie und Onkologie,",
	title = "Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study",
	journal = "Annals of Oncology",
	volume = "18",
	year = "1 April 2007",
	abstract = "<B>Background:</B> We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma.<P></P><B>Patients and methods:</B> Twenty-three patients were treated with HD-MTX on days 1 and 10. In case of at least a partial remission (PR), HD-BuTT followed by aPBSCT was given. Patients without response to induction or without complete remission (CR) after HD-BuTT received WBRT.<P></P><B>Results:</B> Sixteen patients received HD-MTX and HD-BuTT achieving a CR/PR rate of 69%/13%. CR/PR rates for all patients (<I>n</I> = 23) were 70%/13%. There were three deaths during therapy. With longer follow-up three neurotoxic deaths occurred in irradiated patients (<I>n</I> = 9), while no persistent neurotoxicity was seen after HD-BuTT without subsequent WBRT. At a median follow-up of 15 months (range 1-69) median event-free survival (EFS) and overall survival (OS) for all patients were 17 and 20 months (Kaplan-Meier), after HD-BuTT 27 months and `not reached', respectively. Estimated 2-year EFS and OS were 45% and 48% for all patients versus 56% and 61% for the HD-BuTT group, respectively.<P></P><B>Conclusion:</B> MTX induction followed by HD-BuTT is an effective and very short time-on-treatment regimen. Median survival for patients treated with high-dose chemotherapy is not reached yet. The induction regimen needs optimisation. In this study WBRT was associated with a high incidence of severe neurotoxicity.",
	pages = "665-671(7)",
	url = "http://www.ingentaconnect.com/content/oup/annonc/2007/00000018/00000004/art00665"
	doi = "doi:10.1093/annonc/mdl458"
}